Intervention
Fludarabine
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 91 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · 2026-10-12
RECRUITINGA Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung CancerNCT07830342 · 2026-09-21
RECRUITINGGCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid TumoursNCT07297667 · 2026-08-30
RECRUITINGA Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid MalignanciesNCT07613723 · 2026-05-11
RECRUITINGA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesNCT07304154 · 2026-04-10
RECRUITINGSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.NCT07526493 · 2026-04-01
RECRUITINGBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsNCT07523529 · 2026-03-02
RECRUITINGDual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal MesotheliomaNCT07510815 · 2026-03-02
RECRUITINGDual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate CancerNCT07641049 · 2026-03-02
RECRUITINGA Phase 1 Study of ADI-001 in Rheumatoid ArthritisNCT07100873 · 2025-10-10
RECRUITINGA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesNCT07115745 · 2025-09-04
RECRUITINGImmune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaNCT05077527 · 2025-02-13
RECRUITINGA2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast CancerNCT05989828 · 2024-12-17
RECRUITINGCell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT06236139 · 2024-11-26
RECRUITINGA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)NCT06733935 · 2024-11-04
RECRUITINGAutologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCNCT06193486 · 2024-10-26
RECRUITINGTIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerNCT06532799 · 2024-09-10
RECRUITINGTIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerNCT06532812 · 2024-08-22
RECRUITINGTIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerNCT06538012 · 2024-08-20
RECRUITINGOpen-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.NCT06581562 · 2024-05-15
RECRUITINGPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerNCT06121557 · 2023-11-01
RECRUITINGPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT06121570 · 2023-11-01
RECRUITINGStudy of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerNCT05981014 · 2023-08-01
RECRUITINGStudy of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerNCT05981001 · 2023-08-01
RECRUITINGClinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCNCT05681780 · 2023-03-10
RECRUITINGDonor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesNCT05327023 · 2022-05-23
RECRUITINGPhase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesNCT04959175 · 2021-09-23
RECRUITINGStudy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesNCT04282044 · 2021-01-08
RECRUITINGAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerNCT03412877 · 2018-09-06
RECRUITINGLung and Bone Marrow Transplantation for Lung and Bone Marrow FailureNCT03500731 · 2018-04-19
RECRUITINGAdministering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNCT02830724 · 2017-04-06
RECRUITINGT Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerNCT02133196 · 2014-10-23
RECRUITINGReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTNCT01962415 · 2014-02-04
RECRUITINGImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerNCT01174121 · 2010-08-26
RECRUITINGIL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancerNCT07803653 · 2026-10-31
NOT_YET_RECRUITINGA Phase 1/2 Trial of ADI-212 in mCRPCNCT07793435 · 2026-09-01
NOT_YET_RECRUITINGIDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDEDA Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple SclerosisNCT07008378 · 2025-10-15
ACTIVE_NOT_RECRUITINGHS-IT101 Injection for Advanced NSCLCNCT07105176 · 2025-08-30
NOT_YET_RECRUITINGAutologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate CancerNCT06094842 · 2025-04-15
WITHDRAWNPhase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201NCT06341647 · 2024-10-31
WITHDRAWNAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerNCT06253520 · 2024-05-16
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)NCT06220201 · 2024-03-28
ACTIVE_NOT_RECRUITINGNon-Viral TCR Gene TherapyNCT04102436 · 2024-03-08
WITHDRAWNA Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsNCT06237881 · 2024-01-31
ACTIVE_NOT_RECRUITINGA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)NCT05869955 · 2023-09-13
ACTIVE_NOT_RECRUITINGA Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205 · 2023-08-01
WITHDRAWNCISH Inactivated TILs in the Treatment of NSCLCNCT05566223 · 2023-02-01
WITHDRAWNDose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor MalignanciesNCT05694364 · 2023-01-25
COMPLETEDCord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic CancersNCT04083170 · 2022-10-06
TERMINATEDTreatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)NCT05798546 · 2022-09-28
UNKNOWNGenetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint InhibitorsNCT05334329 · 2022-07-20
ACTIVE_NOT_RECRUITINGA Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerNCT05451849 · 2022-06-21
TERMINATEDFT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05395052 · 2022-05-31
TERMINATEDT Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial CancersNCT05035407 · 2022-03-08
TERMINATEDFT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsNCT05069935 · 2021-10-15
TERMINATEDGenetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerNCT04639245 · 2021-07-19
TERMINATEDStudy of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung CancerNCT06048705 · 2021-03-09
TERMINATEDMaster Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid TumorsNCT04526509 · 2020-12-21
TERMINATEDTiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyNCT04596033 · 2020-11-11
TERMINATEDCommon conditions
Breast Cancer16Ovarian Cancer13Melanoma10Non-Small Cell Lung Cancer8Multiple Sclerosis6Triple Negative Breast Cancer6Colorectal Cancer5Breast Neoplasms4Cervical Cancer4Gastric Cancer4Lung Cancer4Pancreatic Cancer4Rheumatoid Arthritis4Acute Lymphoblastic Leukemia3Advanced NSCLC3Chronic Lymphocytic Leukemia3Head and Neck Cancer3Metastatic Castration-resistant Prostate Cancer3Multiple Myeloma3Neoplasms3Non Small Cell Lung Cancer3Renal Cell Carcinoma3Solid Tumor3Solid Tumor, Adult3Squamous Cell Carcinoma3
Leading sponsors
National Cancer Institute (NCI)
15
M.D. Anderson Cancer Center
6
Fred Hutchinson Cancer Center
5
Fate Therapeutics
4
H. Lee Moffitt Cancer Center and Research Institute
4
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
4
Beijing Biotech
3
Essen Biotech
3
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
3
Adaptimmune
2
Adicet Therapeutics
2
Hangzhou Huasai Biomedicine Co., Ltd.
2
Kite, A Gilead Company
2
Masonic Cancer Center, University of Minnesota
2
Paul Szabolcs
2
Trial status mix
RECRUITING34
TERMINATED18
COMPLETED16
ACTIVE_NOT_RECRUITING10
WITHDRAWN5
UNKNOWN4
NOT_YET_RECRUITING3
SUSPENDED1
Phase mix
PHASE173
PHASE241
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.